Skip to main content
Premium Trial:

Request an Annual Quote

MorphoSys Inks Antibody Development, Distribution Agreement with Sigma-Aldrich

This article has been updated to clarify the fact that Sigma-Aldrich is distributing antibodies derived from the HuCAL Gold library.
NEW YORK (GenomeWeb News) – MorphoSys said today it has agreed to a research antibody design and distribution agreement with Sigma-Aldrich.
Under the agreement, MorphoSys’s Serotec business unit will develop and qualify unique recombinant research antibodies from its HuCAL Gold library against targets identified by Sigma-Aldrich, which will distribute the antibodies, MorphoSys said.
Sigma-Aldrich will offer the HuCAL-based antibodies through its Antibody Explorer and Your Favorite Gene search platforms.
The HuCAL-based antibody technology “will allow researchers access to antibody content not available through standard antibody generation technologies,” said David Smoller, president of Sigma-Aldrich’s Research Biotech business unit.
Smoller also said that in conjunction with Sigma-Aldrich’s standard content generation capabilities, the research antibody technology “is expected to allow the community to reach its goal of a binder for every gene and one day even protein in the human body.”
Financial terms of the agreement were not released.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.